7月15日,港股创新药企云顶新耀(1952.HK)宣布,其通用型的现货肿瘤治疗性疫苗EVM14注射液的新药临床试验申请(IND)获国家药品监督管理局药品审评中心(CDE)的正式受理。这是该产品继2025年3月获美国食品药品监督管理局(FDA)批准开展临床后,在全球监管路径上的又一关键进展,该产品由此成为云顶新耀mRNA平台首个实现“中美双报”的产品,标志着公司在全球创新布局上又迈出了关键一步。在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.